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Strengths and limitations of this study
 ► First controlled trial testing the effect of mirtazapine 
in hyperemesis gravidarum.
 ► First placebo- controlled trial investigating the effect 
of oral ondansetron in hyperemesis gravidarum.
 ► Simple study design with relevance to clinical 
practice.
 ► Patient involvement in protocol development and 
patient reported outcomes.
 ► Only patients able to tolerate oral medication can be 
included; thus, the most severe cases of hypereme-
sis gravidarum may be excluded from participation.
AbStrACt
Introduction Current pharmacological treatment options 
for hyperemesis gravidarum have been introduced 
based on scarce evidence and are often not sufficiently 
effective. Several case reports suggest that mirtazapine, 
an antidepressant, may be an effective treatment for 
hyperemesis gravidarum, but so far there are no controlled 
trials investigating the potential effect of mirtazapine on 
hyperemesis gravidarum. The antiemetic ondansetron is 
currently widely used to treat hyperemesis gravidarum 
despite sparse evidence of effect in pregnant women. 
This study aims to investigate the effect of mirtazapine on 
hyperemesis gravidarum while also providing data on the 
effect of ondansetron.
Methods and analysis This randomised double- blind 
placebo- controlled multicentre trial will be conducted in eight 
Danish hospitals. One hundred and eighty pregnant women 
referred to secondary care for hyperemesis gravidarum 
will be randomly allocated to 14- day treatment with either 
mirtazapine, ondansetron or placebo. Main inclusion criterion 
will be Pregnancy Unique Quantification of Emesis (PUQE-24) 
score ≥13 or PUQE-24 score ≥7 if accompanied by weight loss 
>5% of pre- pregnancy weight or hospitalisation. Participants 
are eligible regardless of whether other antiemetics, including 
ondansetron, have been tried. The coprimary outcomes are 
effects of mirtazapine and ondansetron, respectively, on PUQE-
24 score tested hierarchically on day 2 and day 14. Secondary 
outcomes include, but are not limited to, differences between 
the three groups in number of daily vomiting episodes, dropout 
due to treatment failure, use of rescue medication, weight 
change and side effects.
Ethics and dissemination The trial has been approved 
by the Regional Committees on Health Research Ethics 
in the Capital Region of Denmark, the Danish Medicines 
Agency and the Danish Data Protection Agency. Results will 
be published in peer- reviewed journals and submitted to 
relevant conferences.
trial registration number NCT03785691
IntroduCtIon
Hyperemesis gravidarum is one of the leading 
causes of hospitalisation in pregnancy1 and 
current treatment options are used despite 
sparse evidence of effect.
While nausea and vomiting in pregnancy 
is common and most often not severe, 0.3%–
3.6% of pregnant women experience a debil-
itating level of symptoms.2 This condition, 
hyperemesis gravidarum, is characterised 
by severe nausea and vomiting, but diag-
nostic criteria vary.3 It may cause dehydra-
tion, electrolyte imbalances, weight loss and 
hospitalisation. It is associated with maternal 
and neonatal morbidity, lower quality of 
life and can lead to elective termination of 
pregnancy.4–7
Recommendations on pharmacological 
treatment for hyperemesis gravidarum are 
largely based on knowledge obtained from 
general antiemetic treatment with scarce 
evidence on effect and side effects in preg-
nant women. A Cochrane review from 2017 
on interventions for treating hyperemesis 
gravidarum found a limited number of 
placebo- controlled trials.8
In most developed countries, including 
Denmark, no drugs have been approved as 
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Figure 1 Trial design.
treatment for hyperemesis gravidarum or nausea and 
vomiting in pregnancy. Thus, when needed, pharmaco-
logical treatment is used off- label.
Ondansetron, a short- acting 5- HT3 antagonist, is one 
of the most commonly used antiemetics in pregnancy. In 
2014, 22.2% of pregnant women in the USA were treated 
with antiemetics, and of these the majority (89%) used 
oral ondansetron (19.7% of the pregnancies).9 There 
are few controlled trials with oral ondansetron and 
active comparators10 11; however, there are no placebo- 
controlled trials that have investigated oral ondansetron 
for hyperemesis gravidarum or nausea and vomiting in 
pregnancy.
Furthermore, ondansetron and other current pharma-
cological treatment options do not consistently provide 
symptom resolution. Accordingly, treatment with intrave-
nous fluids is common and in rare cases parenteral nutri-
tion is needed.12
Mirtazapine, an appetite stimulating and antiemetic 
antidepressant, may be a promising candidate in the clin-
ical management of hyperemesis gravidarum. The phar-
macological profile resembles that of a long- acting 5- HT3 
antagonist combined with a sedating antihistamine.13 
Mirtazapine is described in 23 case reports as an effec-
tive treatment for hyperemesis gravidarum,14–22 and the 
antiemetic effect is confirmed in a systematic review and 
meta- analysis on mirtazapine for postoperative nausea 
and vomiting.23 However, there are no controlled trials 
with mirtazapine in pregnant women with hyperemesis 
gravidarum.
The aim of this trial is to investigate the effect of 
mirtazapine and ondansetron on nausea and vomiting in 
pregnant women with hyperemesis gravidarum.
MEthodS And AnAlySIS
trial design
This is a randomised double- blind placebo- controlled 
multicentre trial conducted in eight Danish hospitals. We 
plan to randomise 180 participants 1:1:1 to oral treatment 
with either mirtazapine, ondansetron or placebo. The 
intervention proceeds for 2 weeks and all participants 
are allowed to use metoclopramide as rescue medication. 
Trial design is shown in figure 1.
Eligibility
Participants are recruited among patients referred to 
secondary care in departments of gynaecology and 
obstetrics. To be eligible, participants must have Preg-
nancy Unique Quantification of Emesis (PUQE-24) 
score ≥13 or PUQE-24 score ≥7 if accompanied by (1) 
weight loss >5% of pre- pregnancy weight and/or (2) 
hospitalisation due to nausea and vomiting in pregnancy 
or hyperemesis gravidarum. The PUQE-24 score is a vali-
dated score to grade the severity of HG. It ranges 3–15 
with scores ≥13 representing hyperemesis gravidarum24 
(see table 1).
Full list of inclusion and exclusion criteria is shown in 
table 2.
Both inpatients and outpatients are eligible and can be 
recruited on first or subsequent admissions. Participants 
are eligible regardless of whether other antiemetics, 
including ondansetron, have been tried, and concomi-
tant use of first- line treatment (pyridoxine and antihista-
mine) is allowed and will be registered. ECG and blood 
tests must be performed before final decision of inclusion 
to rule out long QT syndrome and elevated creatinine or 
alanine aminotransferase.
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Table 1 Pregnancy Unique Quantification of Emesis 
(PUQE-24) scale
PUQE-24 scoring system
In the last 24 hours, for how long have you felt nauseated or 
sick to your stomach?
Not at all
(1 point)
1 hour or 
less
(2 points)
2–3 hours
(3 points)
4–6 hours
(4 points)
More than
6 hours
(5 points)
In the last 24 hours have you vomited or thrown up?
7 or more 
times
(5 points)
5–6 times
(4 points)
3–4 times
(3 points)
1–2 times
(2 points)
I did not 
throw up
(1 point)
In the last 24 hours how many times have you had retching 
or dry heaves without bringing anything up?
Not at all
(1 point)
1–2 times
(2 points)
3–4 times
(3 points)
5–6 times
(4 points)
7 or more 
times
(5 points)
PUQE-24 score: mild ≤6, moderate 7–12, severe ≥13
On a scale of 0 to 10, how would you rate your well- being?
0 (worst possible) 10 (the best you felt before pregnancy)
PUQE-24, Pregnancy Unique Quantification of Emesis.
Table 2 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
 ► Written informed consent
 ► Female age ≥18 years
 ► Pregnant with gestational age 5+0–19+6
 ► Singleton pregnancy
 ► Nausea and vomiting without other obvious reason
 ► PUQE-24 score ≥13 or PUQE-24 score ≥7 and
a. weight loss >5% of pre- pregnancy weight and/or
b. hospitalisation due to nausea and vomiting in pregnancy 
or hyperemesis gravidarum.
 ► Mola pregnancy, multiple gestation or non- vital pregnancy
 ► Nausea and vomiting of other aetiology than nausea and 
vomiting in pregnancy
 ► Allergic to selective 5- HT3 antagonists
 ► Ongoing treatment with antidepressant medication
 ► Pre- existing diagnosis of chronic kidney disease, diabetes 
type 1 or 2, significant cardiac disease (incl. long QT 
syndrome), epilepsy, HIV. In case of other pre- existing 
conditions, participants might be excluded based on 
individual assessment by an MD
 ► Elevated alanine aminotransferase (>150 U/L)
 ► Elevated creatinine (>100 µmol/L)
 ► ECG showing long QT- syndrome (QTc >460 ms)
 ► Weekly alcohol intake >2 units of alcohol
 ► Not able to take medicine orally
 ► Not able to understand spoken and/or written Danish
 ► Participation in another investigational drug trial within 
current pregnancy
PUQE-24, Pregnancy Unique Quantification of Emesis.
randomisation and blinding
Randomisation and manufacturing of trial medication is 
performed by Glostrup Pharmacy (Glostrup, Denmark). 
Both ondansetron and mirtazapine are encapsulated 
and appear similar to placebo in regard to look, taste 
and smell. Randomisation is computerised via  random-
ization. com creating a unique randomisation number 
for each treatment unit. Randomisation is performed in 
blocks of 3 or 6 and stratified according to study site. The 
study sites receive the trial medication blinded. Each new 
participant is provided with the trial medication with the 
lowest available randomisation number at that specific 
study site.
The randomisation lists are held by Glostrup Pharmacy 
until the end of the trial.
Interventions
The intervention proceeds for 14 (±1) days as either inpa-
tient or outpatient.
All trial medications are oral tablets and administration 
of trial medication starts at bedtime of the day of rando-
misation (visit 1 on day 0). During week 1, trial medica-
tion is administered at bedtime and in the morning. If a 
participant vomits within 45 minutes after administration, 
one readministration is encouraged.
During the first week, the bedtime administration in the 
mirtazapine group contains mirtazapine 15 mg and the 
morning administration contains placebo. In the ondan-
setron group, both morning and bedtime administrations 
contain ondansetron 8 mg, whereas in the placebo group, 
morning and bedtime administrations contain placebo.
In case of insufficient symptom relief, an increase in 
dosage is optional at visit 2 on day 7 (±1). If desired, the 
number of administrations in week 2 is increased to four 
daily with administrations in the morning, at lunch, late 
afternoon and bedtime.
In case of dosage increase, the bedtime administration 
in the mirtazapine group contains mirtazapine 30 mg and 
the administrations in the morning, at lunch and late 
afternoon contain placebo. In the ondansetron group, 
all four administrations contain ondansetron 8 mg, and 
in the placebo group, all four administrations contain 
placebo.
If dosage increase is not desired, the treatment regimen 
in the first week (week 1) continues in the second week 
(week 2).
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Table 3 Trial schedule—outcomes (pro: patient- reported outcomes)
Visit 1
Day 0
Randomisation
Visit 2
Day 7 (±1)
Visit 3
Day 14 (±1)
End of intervention
Daily online 
questionnaires
1 month after 
delivery
PUQE-24 score PRO PRO PRO PRO
PUQE well- being score PRO PRO PRO PRO
Nausea VAS PRO PRO PRO PRO
Daily vomiting episodes PRO PRO PRO PRO
Administration of trial 
medication
      PRO
Administration of rescue 
medication
      PRO
Side effects Registered by trial 
personnel
Registered by trial 
personnel
Registered by trial 
personnel
PRO
NVPQOL PRO PRO PRO   
HELP- score PRO PRO PRO   
EQ5D- 5L PRO PRO PRO   
Modified PSQI PRO PRO PRO   
Patient satisfaction with 
treatment VAS
  PRO PRO   
Patient consideration of 
termination of pregnancy
PRO PRO PRO   
Request for dosage increase   Registered by trial 
personnel
    
Request for continued 
treatment
    Registered by trial 
personnel
  
Days on sick leave   PRO PRO   
Intravenous fluid therapy   PRO PRO   
Days of hospitalisation   PRO PRO   
Weight Measured by trial 
personnel
Measured by trial 
personnel
Measured by trial 
personnel
  
Pregnancy outcome 
including possible 
malformation and 
hospitalisation of the new- 
born
        Collected from 
medical record
Treatment failure Registered by trial personnel at time of event
PUQE, Pregnancy Unique Quantification of Emesis; VAS, visual analogue score.
Administration of metoclopramide as rescue medica-
tion is allowed for all participants in case of insufficient 
symptom relief as is treatment with intravenous fluids 
according to local procedures. All participants will be 
instructed to take a vitamin B supplement daily containing 
15 mg thiamine, 15 mg riboflavin and 15 mg pyridoxine.
The intervention ends on day 14 (±1).
Study procedures
Participation in the trial includes three visits of approxi-
mately 30–45 min each.
After obtainment of written informed consent, trial 
specific procedures can be performed to assess possible 
unclear inclusion and exclusion criteria. This might 
include renewed ultrasound scan to confirm viable 
singleton pregnancy, ECG and blood tests to rule out 
long QT- syndrome and elevated creatinine and alanine 
aminotransferase. Obstetric history and concomitant 
medications including all medications administered 
during current pregnancy are recorded, and participants 
undergo a physical examination.
Visit 1 (day 0) takes place before any administration of 
trial medication and may take place on the same day as 
informed consent and assessment of eligibility criteria. 
At this visit, baseline data are collected including patient 
reported outcomes which are filled in to online question-
naires by participants (please refer to table 3). Participants 
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are weighed and vital signs are measured. Blinded trial 
medication is dispensed and participants are instructed 
to start administration of trial medication on the evening 
of the day of visit 1. Likewise, participants are instructed 
to administer the dispensed vitamin B daily and metoclo-
pramide if needed. Participants are instructed to fill out 
daily online questionnaires during the intervention.
At visit 2 (day 7 (±1)), participants again fill out online 
questionnaires on patient- reported outcomes. Weight 
and vital signs are measured, and changes in concomi-
tant medication are registered, compliance is assessed, 
and participants are asked if they experienced other side 
effects than those registered in the daily online question-
naires, and dosage increase is offered in case of insuffi-
cient symptom relief. New trial medication is dispensed, 
and next visit is scheduled.
At visit 3 (end of intervention on day 14 (±1)), patient- 
reported outcomes are again recorded via online question-
naires. Weight and vital signs are measured, and changes 
in concomitant medication are recorded and compliance 
assessed. Participants are asked if they experienced other 
side effects than those registered in the daily online ques-
tionnaires, and if they desire to continue treatment after 
the intervention, unblinding of the specific participant 
is possible. Thereafter, no effect measures are collected, 
but daily registration of side effects continues until 5 days 
after end of intervention.
For all participants, blood samples and ECG are collected 
before randomisation and at visit 2 and 3 to confirm compli-
ance with eligibility criteria. Blood samples from visit 2 and 
3 are kept for plasma- mirtazapine and plasma- ondansetron 
analysis after the end of the trial. Blood samples from visit 1 
and 3 are kept for future research.
After pregnancy, delivery and pregnancy outcome as well 
as possible hospitalisation of the newborn are registered.
outcome measures
Primary outcome
The primary outcome is the patient- reported outcome 
PUQE-24 score which is collected in online questionnaires 
filled in by participants on day 2 and day 14. Differences 
between baseline values and values recorded during or at 
end of intervention will be compared.
Secondary outcomes
Secondary outcomes mainly include patient- reported 
outcomes but also outcomes registered by trial personnel.
All outcomes including timings are listed in table 3.
Questionnaires
The online questionnaires at visit 1, 2 and 3 include 
PUQE-24 score, nausea visual analogue scale (VAS), 
number of daily vomiting episodes, Health- Related 
Quality of Life for Nausea and Vomiting during Pregnancy 
(NVPQOL), Hyperemesis Level Prediction (HELP), 
health related quality of life (EQ5D- 5L), modified Pitts-
burgh Sleep Quality Index (PSQI) and a question on 
consideration of termination of pregnancy. At visit 2 and 
3, questionnaires also include satisfaction- with- treatment 
VAS, number of days on sick leave, hospitalisation and 
number of intravenous fluid treatments. The question-
naires take approximately 15 min to fill out.
The daily online questionnaires are less extensive and 
include PUQE-24 score, nausea VAS, number of daily 
vomiting episodes, registration of side effects and admin-
istration of trial and rescue medication. These can be 
filled out in 2–5 min.
Side effects
Participants are prompted to register side effects in the 
daily online questionnaires. Moreover, participants will be 
asked about side effects at visit 2 and 3, and trial personal 
register further side effects.
Treatment failure
If a participant withdraws from the trial before the end of 
the intervention, the reason for withdrawal is registered. 
If the reason is insufficient antiemetic effect of the trial 
medication, treatment failure is registered as reason for 
withdrawal and time of treatment failure is recorded.
Pregnancy outcome
Pregnancy outcome include registration of whether the 
pregnancy resulted in live birth, loss of or termination of 
pregnancy, mode of delivery, complications, birth weight, 
gestational age at birth, APGAR score, umbilical cord pH, 
weight of the placenta, sex of the newborn, congenital 
malformations and hospitalisation of the newborn during 
the first month postpartum.
data collection
The secure browser- based system REDCap (REDCap 
Consortium, Vanderbilt University, USA) is used as data 
collection tool.25 All patient- reported outcomes are 
recorded directly in REDCap by participants filling out 
online questionnaires via secure email links. Data regis-
tered by trial personnel at the visits are entered directly 
in REDCap. Data on pregnancy and delivery outcome 
are collected from participant’s and newborn’s medical 
records and entered in REDCap.
Monitoring
The trial is subject to ongoing monitoring by the Danish 
units for Good Clinical Practice (GCP- units, https:// gcp- 
enhed. dk/ en/ gcpunits/) in accordance with Interna-
tional Conference on Harmonisation for Good Clinical 
Practice (ICH- GCP).
Statistical analysis
Sample size
The trial is dimensioned to detect a difference of 2 or 
more in the coprimary outcomes; change in PUQE-24 
score from baseline to day 2 in the mirtazapine versus 
the placebo group, or in the ondansetron versus the 
placebo group. Each hypothesis for coprimary outcomes 
will be tested at significance level 2.5% in order to obtain 
at family- wise type I error of 5% based on a Bonferroni 
correction. The power calculation is based on a standard 
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deviation of change in PUQE-24 score of 3, which is a 
conservative estimate based on a placebo- controlled 
trial with doxylamine- pyridoxine.26 Expecting dropout 
of 35%, 58 participants are required in each of the three 
groups to obtain a power of 80%. Rounding that up to 
60 participants, we aim to include 180 participants in 
total.
Planned analysis
The primary analysis will consist of a linear model with 
intervention group and baseline PUQE-24 score as covari-
ates adjusted for site due to the stratified design. Intention 
to treat analysis will be performed where participants will 
be included in the analysis irrespectively of their adher-
ence to the protocol. Primary and secondary outcomes 
will be tested hierarchically to control the family- wise 
error rate.
Significance of the primary outcome will be assessed by 
comparing differences in PUQE-24 score from baseline 
to day 2 in the mirtazapine versus the placebo group and 
similarly in the ondansetron versus the placebo group. If 
significance is obtained at day 2, a subsequent analysis will 
be performed at day 14. Difference between mirtazapine 
and ondansetron will be compared as part of the hierar-
chical testing if mirtazapine is significantly different from 
placebo.
The treatment effect for the primary outcomes will be 
presented as the mean difference between the groups in 
PUQE-24 score change from baseline to day 2 from base-
line to day 14, respectively. Results will be reported with 
95% CI.
Subgroup analyses will be performed by stratifying on 
the baseline variables PUQE-24 score, number of daily 
vomiting episodes, gestational age and concomitant 
medication with first- line treatment.
Per protocol analysis including only participants who 
completed the intervention will be performed as well 
as sensitivity analyses using multiple imputation where 
the imputation model will include all available baseline 
variables.
There are no planned interim analyses.
The statistician performing the analyses will remain 
blinded until the analysis results are closed.
Patient and public involvement
Representatives from Danish and English hyperemesis 
gravidarum patient organisations were consulted in the 
development of the trial and reviewed the protocol. 
They provided valuable insight which led to consid-
erations of ethical issues as well as feasibility, which 
resulted in changes in inclusion criteria, outcome 
measures and option of continued treatment after end 
of intervention. The trial is considered a priority by the 
Danish Society of Obstetrics and Gynaecology’s Multi-
centre Consortium, whom are supporting the trial. We 
plan to inform the trial participants of the final results 
if requested.
discussion of design
Relevance
This is the first controlled trial to test mirtazapine as 
treatment for hyperemesis gravidarum and it is to our 
knowledge the first trial to test oral ondansetron for 
hyperemesis gravidarum and nausea and vomiting in 
pregnancy in a placebo- controlled setting. While the indi-
vidual participants may not directly benefit from partici-
pating in the trial, the trial will provide data on the effect 
of mirtazapine; a new and possibly more effective treat-
ment for hyperemesis gravidarum which may reduce the 
burden of this debilitating condition. Furthermore, data 
from this trial will fill a knowledge gap on the effect of 
ondansetron; a commonly used treatment introduced 
despite sparse evidence of effect in pregnant women.
Safety
Pregnant women are not regularly included in medical 
trials and a central concern has been an assessment on 
whether the trial medications are safe to use in early 
pregnancy.
Based on the reviewed literature with more than 2000 
mirtazapine exposed pregnancies (presumably prescribed 
on the indication depression or anxiety), we consider the 
use in pregnancy safe.27–31
A systematic review of ondansetron exposure in preg-
nancy and risk of congenital malformations conclude that 
the overall risk of congenital malformations is low, but 
results on risk of oral clefts and cardiac malformations 
are conflicting.32 However, two recent cohort studies, 
one including almost 90 000 pregnancies exposed to 
prescription ondansetron and one including over 23 000 
pregnancies exposed to intravenous ondansetron, did 
not find an association between exposure and cardiac 
or general congenital malformations in the newborn. 
They did, however, find that exposure was associated 
with a small increased risk of oral cleft (3 in 10 000).33 34 
Considering this relatively small increased risk and the 
fact that ondansetron is already being used in pregnant 
women with hyperemesis gravidarum, compared with the 
risk of severe hyperemesis gravidarum, we find it ethically 
acceptable to randomise participants to treatment with 
ondansetron. All participants are informed about the risk 
of oral cleft.
Assessment of adverse events is carried out throughout 
the trial. The trial investigator will assess severity and rela-
tion to trial medication. Serious adverse events will be 
reported to the sponsor, monitor and relevant authorities.
Allocating patients to placebo treatment
Randomising to treatment with placebo in patients 
suffering from this serious condition has been a concern 
of ours. However, due to the lack of placebo- controlled 
trials with ondansetron, interpretation of the study would 
be hampered as it is currently not known to what degree 
(if any) ondansetron relieves the symptoms compared 
with no treatment, especially considering the self- limiting 
nature of the disease. Hence, showing that mirtazapine 
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is as effective as ondansetron without a placebo group 
would not prove that mirtazapine is effective. In addition, 
all participants are allowed to use metoclopramide in case 
of insufficient symptom relief.
Eligibility criteria
A central matter in this trial is the severity of nausea and 
vomiting in pregnancy required to be eligible for partic-
ipation. Diagnostic criteria for hyperemesis gravidarum 
lack international consensus and inclusion criteria vary 
substantially among previously conducted trials on the 
condition.3 Most frequently reported inclusion criteria 
include vomiting, nausea, need for hospital treatment, 
weight loss and ketonuria. However, no studies have 
disclosed an association between ketonuria and severity 
of hyperemesis gravidarum, and the use of ketonuria as a 
diagnostic criteria for hyperemesis gravidarum is thus not 
recommended.35 36
In this trial, the severity of nausea and vomiting in 
pregnancy required for participation is dependent on 
PUQE-24 score which is a validated questionnaire that 
grades the severity of nausea and vomiting in preg-
nancy. The inclusion criterion on severity of the condi-
tion is PUQE-24 score ≥13 (severe nausea and vomiting 
in pregnancy) or PUQE-24 score ≥7 (moderate nausea 
and vomiting in pregnancy) if accompanied by either 
(1) weight loss >5% of prepregnancy weight or (2) hospi-
talisation due to nausea and vomiting in pregnancy or 
hyperemesis gravidarum.
Intervention
It has been a concern whether this patient population 
would be able to tolerate oral medication and thus both 
intravenous, rectal, sublingual and orally dissolving 
administration of trial medication have been considered. 
However, mirtazapine is only commercially available in 
a tablet and orally dissolving tablet formulation. While 
the orally dissolving tablet would be easier to swallow, 
the strong taste is not well tolerated. We have therefore 
decided to use oral tablets as trial medication even though 
we might exclude the most severe cases of hyperemesis 
gravidarum due to the exclusion criterion ‘not able to 
take trial medication orally’.
The duration of the intervention is 14 days in accor-
dance with previous pharmacological trials on nausea and 
vomiting in pregnancy and hyperemesis gravidarum.10 26 
A longer lasting intervention would increase the likeli-
hood that a possible decrease in symptoms might be due 
to the self- limiting nature of nausea and vomiting in preg-
nancy rather than a consequence of the intervention and 
would reduce a difference between the placebo group 
and the two active treatments.
The Danish guideline on hyperemesis gravidarum 
recommends treatment with ondansetron 8 mg twice 
daily with optional increase to a maximum total dosage 
of 32 mg daily.37 The treatment in the ondansetron group 
thus reflects current practice.
Most of the case reports on mirtazapine and hyperem-
esis gravidarum describe dosages of up to 15 mg daily to 
be effective. However, in some case reports the initial 
dosage was mirtazapine 30 mg daily.16 17 22 Thus, to not 
disregard a possible effect due to inadequate dosage 
and better reflect the usage outside a clinical study, this 
trial allows for an optional dosage increase to 30 mg 
mirtazapine daily.
Outcomes
Patient- reported outcomes are prioritised over objec-
tive measures because this reflects current practice in 
assessing severity of symptoms in patients with hyperem-
esis gravidarum where few objective measures are assessed. 
However, previous trials have had difficulties obtaining 
complete records for patient- reported outcomes.38 
Therefore, we have kept the daily online questionnaires 
short so answering them will be feasible even for severely 
affected participants. The more extensive questionnaires 
are part of the trial visits and thus personnel will ensure 
collection of these data.
The primary outcomes difference in PUQE-24 score 
from baseline to day 2 evaluates the short- term effect of 
the active medications versus placebo. Previous trials in 
hyperemesis gravidarum have evaluated treatment effect 
at the end of the intervention; however, they have had 
issues with missing data due to dropouts during the inter-
vention, especially in the placebo groups.39 The VOMIT 
trial is conducted without a pilot trial and the first 10 
months of recruiting may be viewed as a pilot phase. Like 
previous trials, we have had a high rate of dropouts due 
to treatment failure and we have adjusted the primary 
endpoint accordingly. We have introduced the primary 
outcome on day 2 as participants are more likely to still 
be in the trial and treatment effect is expected to be estab-
lished at this point. Furthermore, this early endpoint 
diminishes the likelihood of a possible symptom reduc-
tion being due to the self- limiting nature of nausea and 
vomiting in pregnancy rather than a consequence of the 
intervention. If results are statistically significant on day 2, 
we will proceed to run analyses on data from day 14.
The outcome treatment failure further enables analyses 
between the groups in case of dropouts.
Unblinding after end of intervention in case of desire to continue 
trial medication
Most guidelines recommend ondansetron for severe 
cases of hyperemesis gravidarum and thus, we have 
discussed whether this should be the treatment offered 
to participants after the intervention. However, in several 
case reports, mirtazapine has been effective when ondan-
setron has not.14 18 22 Thus, in the event that a participant 
has experienced significant symptom relief during the 
intervention and therefore wishes to continue the trial 
medication, we find it unethical not to offer this. This 
requires unblinding which will happen after the main 
outcome has been collected and consequently with no 
influence on the internal validity. This option is supported 
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by patient representatives and has been approved by the 
statistical consultant.
EthICS And dISSEMInAtIon
Approvals and registrations
The study protocol has been approved by the Regional 
Committees on Health Research Ethics in the Capital 
Region of Denmark (H-18047191), the Danish Medicines 
Agency (EudraCT: 2018-002285-39) and the Danish Data 
Protection Agency (P-2019-75). The manufacturers of 
mirtazapine and ondansetron have been notified about 
the trial, but have not contributed to the protocol, nor 
have they made financial contributions. The protocol is 
published on  clinicaltrials. gov.
dissemination
The results of the study will be published in a peer- 
reviewed journal and submitted to relevant conferences. 
Additionally, trial participants will be informed of the 
results.
The results of this trial may be integrated in future 
recommendations on hyperemesis gravidarum.
trial status
Recruiting started in March 2019 and the trial is currently 
recruiting at five sites. Recruiting is planned to open at 
three more sites during early 2020 and last participant 
included is expected in late 2021 with collection of preg-
nancy outcome and end of trial in mid 2022.
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